Eyubova Ulviyya
Azerbaijan Medical University, Baku, Azerbaijan
Title: Recent advances in the pathogenetic treatment of heart failure
Biography
Biography: Eyubova Ulviyya
Abstract
Actuality: The 2017 data shows that 26 million people worldwide suffer from heart failure. This number increases every year for a number of reasons in all countries of the world. Numerous studies in recent years have revealed important advances in the treatment of the disease. One of them is the detailed study of the role of BNP in your disease category and the use of therapeutic approaches according to this role.
The aim was to study the effects of the sacubitril / valsartan combination on the patients with chronic heart failure of II-IV functional classification according to the NHYA classification.
Materials and methods: The results of 30 male and female patients with functional heart failure II classification according to NHYA classification were researched. Patients were over 25 years of age. Each patient was given a combination of sacubitril / valsartan 200mg daily (100mg in the morning and 100mg in the evening). After 6 months, the functional class was re-evaluated.
Results of our study: At the time of re-examination after 6 months, an improvement was observed in the indications of functional classification of 20 patients.
Conclusion: As a result of the study, we found that the addition of sacubitril / valsartan combination to the treatment of chronic heart failure has an important effect in patients.